Educational reference only. Not medical advice. Consult a healthcare provider before starting any protocol.

Library

Tesamorelin

Tesamorelin Acetate (TH9507)

Fat lossMuscleSleepHormone44 amino acids

What it is

A synthetic 44-amino-acid modified GHRH analogue with a trans-3-hexenoic acid group at the N-terminus conferring enhanced resistance to DPP-IV enzymatic degradation. Tesamorelin is FDA-approved (as Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, making it the only GH secretagogue with an active FDA-approved indication. It has been studied in Phase 3 randomized controlled trials demonstrating selective reduction of visceral adipose tissue and is discussed in optimization communities in the context of body composition, metabolic health, and anti-aging protocols.

Community-reported ranges

Ranges sourced from FDA prescribing information (Egrifta labels), published Phase 3 clinical trial data, and community forums. Not dosing guidance.

Reported dose range

10002000 mcg

Estimated half-life

~26-38 minutes (varies by formulation and population)

Source: FDA prescribing information (Egrifta / Egrifta SV / Egrifta WR labels, NDA 22-505)

Reported cycle length

812 weeks on

4 weeks off

Route

subcutaneous

Common vial sizes

2mg

Reported timing

Before bedtime, fasted (≥90 min after last meal)

Reported frequency

1x daily

Frequently discussed alongside

Based on community forum discussions. Not a recommendation to combine compounds.

Published research

Tesamorelin was evaluated in pooled Phase 3 RCTs (Falutz et al. 2010, PMID 20554713) demonstrating significant reduction of visceral adipose tissue in HIV lipodystrophy. Stanley et al. (2014, PMID 25038357) showed reduction of liver fat in a JAMA-published RCT. Clemmons et al. (2017, PMID 28617838) studied metabolic effects in type 2 diabetes. The FDA-approved dose is 1.4 mg (Egrifta SV) or 1.28 mg (Egrifta WR) daily via subcutaneous injection. Community-reported off-label use ranges are derived from clinical dosing and published literature.

Reported side effects

From community self-reports. Not from controlled studies.

From FDA prescribing information and clinical trials (>5% incidence): arthralgia, injection site reactions (erythema, pruritus, pain — 25% vs 14% placebo), pain in extremity, peripheral edema, myalgia. Warnings include hyperglycemia/glucose intolerance, hypersensitivity reactions (~4%), fluid retention, anti-drug antibody formation (~49.5% at 26 weeks without significant efficacy impact), and contraindication in active malignancy and pregnancy. Community users have reported water retention in early weeks, carpal tunnel-like symptoms, and morning joint stiffness.

Regulatory status

FDA (United States)

FDA-approved. NDA 22-505, initially approved November 10, 2010. Current formulations: Egrifta SV (2 mg/vial, 1.4 mg daily) and Egrifta WR (11.6 mg/vial, 1.28 mg daily, approved March 2025). Reclassified as a biologic under BPCIA in March 2020 — cannot be legally compounded by 503A pharmacies.

Health Canada

DIN 02423677 approved April 29, 2014 (Egrifta, 2 mg/vial). Status listed as 'Cancelled Pre Market' as of July 13, 2023, likely related to formulation transition.

WADA (Competitive Athletes)

Prohibited at all times under S2.2.4 — Growth Hormone Releasing Factors. Specifically named alongside sermorelin. Classified as a Specified Substance.

Requires free account · 7-day trial included